In this context, the small molecules screened and developed to recover mutants of the CFTR represent the paradigm of how pharmacological chaperons or proteostasis regulators can be successfully used to treat a severe conformational disease like CF [21,38,40]. The gene discussed is CFTR; the disease is cystic fibrosis.